Expression profile of miRNA in NSCLC tissues in middle‑altitude area

Gu,Yuhai; Shi,Xuefeng; Wang,Xinying; Liu,Xia; Xie,Youbang

doi:10.3892/ol.2019.11176

Expression profile of miRNA in NSCLC tissues in middle‑altitude area

Authors:
- Yuhai Gu
- Xuefeng Shi
- Xinying Wang
- Xia Liu
- Youbang Xie
View Affiliations

Affiliations: Department of Respiratory Medicine, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, P.R. China, Graduate School of Qinghai University, Xining, Qinghai 810000, P.R. China, Department of Hematology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, P.R. China
Published online on: December 3, 2019 https://doi.org/10.3892/ol.2019.11176
Pages: 783-794
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Micro ribonucleic acid (miRNA) expression profile in non‑small cell lung cancer (NSCLC) tissues in middle‑altitude area was analyzed using the Affymetrix chip technique, to predict the target genes of abnormally‑expressed miRNAs, and to analyze the target gene‑related signaling pathways and cell biological functions regulated by them. The difference in miRNA expression profile in NSCLC tissues was analyzed using the Affymetrix chip technique. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed for the verification of some differentially‑expressed miRNAs. The genes predicted by at least 6 out of 12 commonly used prediction methods of miRNA target genes, based on miRWalk2.0, were considered as target genes. The functions of differentially‑expressed miRNA target genes were analyzed via Gene Ontology (GO) enrichment analysis, and the main signaling pathways involving target genes were analyzed via Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. There was abnormal expression of miRNAs in NSCLC tissues in the middle‑altitude area. There were 140,405 target genes predicted for differentially‑expressed miRNAs. The GO enrichment analysis of the functions of the target genes of differentially expressed miRNAs revealed that they mainly influence the binding process of intracellular components to protein, the positive regulation of biological process and the regulation of metabolic process. Moreover, these target genes were mainly enriched in the immunity, gene expression, metabolism and signal transduction, among which signal transduction was enriched with the most genes. The expression levels of miRNA‑139‑5p and miRNA‑150‑5p in lung cancer group were lower than those in the control group. The expression of miRNAs in NSCLC tissues in the middle‑altitude area is abnormal, and most miRNAs are downregulated.

View Figures

View References

1	Schreiber G and McCrory DC: Performance characteristics of different modalities for diagnosis of suspected lung cancer: Summary of published evidence. Chest. 123 (Suppl 1):115S–128S. 2003. View Article : Google Scholar : PubMed/NCBI
2	Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
3	Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC and Wang ZX: MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol. 56:645–654. 2012. View Article : Google Scholar : PubMed/NCBI
4	Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 16:430–441. 2010. View Article : Google Scholar : PubMed/NCBI
5	Petriella D, De Summa S, Lacalamita R, Galetta D, Catino A, Logroscino AF, Palumbo O, Carella M, Zito FA, Simone G, et al: miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. Tumour Biol. 37:5503–5513. 2016. View Article : Google Scholar : PubMed/NCBI
6	Heller G, Altenberger C, Steiner I, Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A, Zehetmayer S, Döme B, et al: DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients. J Pathol. 245:387–398. 2018. View Article : Google Scholar : PubMed/NCBI
7	van Rooij E: The art of microRNA research. Circ Res. 108:219–234. 2011. View Article : Google Scholar : PubMed/NCBI
8	Pedersen AK, Mendes Lopes de Melo J, Mørup N, Tritsaris K and Pedersen SF: Tumor microenvironment conditions alter Akt and Na⁺/H⁺ exchanger NHE1 expression in endothelial cells more than hypoxia alone: Implications for endothelial cell function in cancer. BMC Cancer. 17:5422017. View Article : Google Scholar : PubMed/NCBI
9	Petrova V, Annicchiarico-Petruzzelli M, Melino G and Amelio I: The hypoxic tumour microenvironment. Oncogenesis. 7:102018. View Article : Google Scholar : PubMed/NCBI
10	Lanikova L, Reading NS, Hu H, Tashi T, Burjanivova T, Shestakova A, Siwakoti B, Thakur BK, Pun CB, Sapkota A, et al: Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget. 8:11739–11747. 2017. View Article : Google Scholar : PubMed/NCBI
11	Mirsadraee S, Oswal D, Alizadeh Y, Caulo A and van Beek E Jr: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
14	Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI
15	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
16	Kanehisa M and Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
17	Lin PY, Yu SL and Yang PC: MicroRNA in lung cancer. Br J Cancer. 103:1144–1148. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wang Q, Wang S, Wang H, Li P and Ma Z: MicroRNAs: Novel biomarkers for lung cancer diagnosis, prediction and treatment. Exp Biol Med (Maywood). 237:227–235. 2012. View Article : Google Scholar : PubMed/NCBI
19	Vannini I, Fanini F and Fabbri M: MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem. 46:918–925. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
21	Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 26:462–469. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
23	Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, Tsao MS, Penn LZ and Jurisica I: Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA. 106:2824–2828. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 5:e103122010. View Article : Google Scholar : PubMed/NCBI
25	Yu N, Zhang Q, Liu Q, Yang J and Zhang S: A meta-analysis: microRNAs' prognostic function in patients with nonsmall cell lung cancer. Cancer Med. 6:2098–2105. 2017. View Article : Google Scholar : PubMed/NCBI
26	Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et al: Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sun C, Sang M, Li S, Sun X, Yang C, Xi Y, Wang L, Zhang F, Bi Y, Fu Y, et al: Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with downregulation of c-Met. Oncotarget. 6:39756–39792. 2015. View Article : Google Scholar : PubMed/NCBI
28	Watanabe K, Amano Y, Ishikawa R, Sunohara M, Kage H, Ichinose J, Sano A, Nakajima J, Fukayama M, Yatomi Y, et al: Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer. Cancer Med. 4:1573–1582. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xu W, Hang M, Yuan CY, Wu FL, Chen SB and Xue K: MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. Int J Clin Exp Pathol. 8:3864–3870. 2015.PubMed/NCBI
30	Dahlmans D, Houzelle A, Andreux P, Jörgensen JA, Wang X, de Windt LJ, Schrauwen P, Auwerx J and Hoeks J: An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism. Mol Metab. 6:1429–1442. 2017. View Article : Google Scholar : PubMed/NCBI
31	Scrutinio D, Conserva F, Passantino A, Iacoviello M, Lagioia R and Gesualdo L: Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: A genome-wide prospective study. J Heart Lung Transplant. 36:616–624. 2017. View Article : Google Scholar : PubMed/NCBI
32	Palagani A, Op de Beeck K, Naulaerts S, Diddens J, Sekhar Chirumamilla C, Van Camp G, Laukens K, Heyninck K, Gerlo S, Mestdagh P, et al: Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS One. 9:e1138422014. View Article : Google Scholar : PubMed/NCBI
33	Filipska M, Skrzypski M, Czetyrbok K, Stokowy T, Stasiłojć G, Supernat A, Jassem J, Żaczek AJ and Bigda J: miR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer. 118:111–118. 2018. View Article : Google Scholar : PubMed/NCBI
34	Świtlik W, Karbownik MS, Suwalski M, Kozak J and Szemraj J: miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Cancer Biomark. 21:479–488. 2018. View Article : Google Scholar : PubMed/NCBI
35	Narita M, Shimura E, Nagasawa A, Aiuchi T, Suda Y, Hamada Y, Ikegami D, Iwasawa C, Arakawa K, Igarashi K, et al: Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and −200c. PLoS One. 12:e01721152017. View Article : Google Scholar : PubMed/NCBI